Free Trial
NASDAQ:GHRS

GH Research Q2 2024 Earnings Report

GH Research logo
$12.41 +0.31 (+2.56%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$12.42 +0.02 (+0.12%)
As of 08/8/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GH Research EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Monday, September 2, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

GH Research's Q2 2025 earnings is scheduled for Tuesday, September 2, 2025

Earnings Documents

GH Research Earnings Headlines

GH Research PLC (NASDAQ:GHRS) Receives $32.00 Average PT from Brokerages
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
GH Research PLC Approves Key Resolutions at Annual Meeting
TD Cowen Keeps Their Buy Rating on GH Research (GHRS)
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS), together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

View GH Research Profile

More Earnings Resources from MarketBeat